GlassScriptPhysician profile
James J Obrien
NPI 1770578031
$13,950.55
in general payments reported to CMS, 2019-2025
16 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,754 · 2020: $2,379 · 2021: $355 · 2022: $2,466 · 2023: $462 · 2024: $325 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Travel and Lodging: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.36 |
| Travel and Lodging | $952.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5,507.68 | 2019-2023 | Lifevest |
| Abbott Laboratories | $3,245.18 | 2022-2025 | Aveir, Mitraclip |
| Medtronic Vascular, INC. | $2,200.38 | 2020 | |
| Boston Scientific Corporation | $1,629.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $819.16 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $172.83 | 2019-2023 | |
| Medtronic, INC. | $131.72 | 2023 | Arctic Front Advance |
| E.R. Squibb & Sons, L.L.C. | $64.48 | 2021-2023 | Eliquis |
| Lexicon Pharmaceuticals, INC. | $50.22 | 2023 | Inpefa |
| Grt US Holding, INC. | $42.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.24 | 2022 | |
| Glaxosmithkline, LLC. | $20.43 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.18 | 2019 | |
| B. Braun Interventional Systems INC. | $12.97 | 2023 | No Marketed Product Name |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.